255 related articles for article (PubMed ID: 17419606)
1. Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms.
Vock CA; Ang WH; Scolaro C; Phillips AD; Lagopoulos L; Juillerat-Jeanneret L; Sava G; Scopelliti R; Dyson PJ
J Med Chem; 2007 May; 50(9):2166-75. PubMed ID: 17419606
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, characterization, and in vitro evaluation of novel ruthenium(II) eta6-arene imidazole complexes.
Vock CA; Scolaro C; Phillips AD; Scopelliti R; Sava G; Dyson PJ
J Med Chem; 2006 Sep; 49(18):5552-61. PubMed ID: 16942028
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands.
Habtemariam A; Melchart M; Fernandez R; Parsons S; Oswald ID; Parkin A; Fabbiani FP; Davidson JE; Dawson A; Aird RE; Jodrell DI; Sadler PJ
J Med Chem; 2006 Nov; 49(23):6858-68. PubMed ID: 17154516
[TBL] [Abstract][Full Text] [Related]
4. A novel ruthenium(II) arene based intercalator with potent anticancer activity.
Ruiz J; Vicente C; de Haro C; Bautista D
Dalton Trans; 2009 Jul; (26):5071-3. PubMed ID: 19562164
[TBL] [Abstract][Full Text] [Related]
5. Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity.
Peacock AF; Parsons S; Sadler PJ
J Am Chem Soc; 2007 Mar; 129(11):3348-57. PubMed ID: 17319668
[TBL] [Abstract][Full Text] [Related]
6. Chloro half-sandwich osmium(II) complexes: influence of chelated N,N-ligands on hydrolysis, guanine binding, and cytotoxicity.
Peacock AF; Habtemariam A; Moggach SA; Prescimone A; Parsons S; Sadler PJ
Inorg Chem; 2007 May; 46(10):4049-59. PubMed ID: 17441712
[TBL] [Abstract][Full Text] [Related]
7. New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes.
Hotze AC; Bacac M; Velders AH; Jansen BA; Kooijman H; Spek AL; Haasnoot JG; Reedijk J
J Med Chem; 2003 Apr; 46(9):1743-50. PubMed ID: 12699392
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, crystal structure, studies in solution and cytotoxicity of two new fluorescent platinum(II) compounds containing anthracene derivatives as a carrier ligand.
Marqués-Gallego P; den Dulk H; Brouwer J; Kooijman H; Spek AL; Roubeau O; Teat SJ; Reedijk J
Inorg Chem; 2008 Dec; 47(23):11171-9. PubMed ID: 18975941
[TBL] [Abstract][Full Text] [Related]
9. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis.
Ang WH; Daldini E; Scolaro C; Scopelliti R; Juillerat-Jeannerat L; Dyson PJ
Inorg Chem; 2006 Oct; 45(22):9006-13. PubMed ID: 17054361
[TBL] [Abstract][Full Text] [Related]
10. Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity.
Dougan SJ; Melchart M; Habtemariam A; Parsons S; Sadler PJ
Inorg Chem; 2006 Dec; 45(26):10882-94. PubMed ID: 17173447
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, characterization, and in vitro antitumor properties of tris(hydroxymethyl)phosphine copper(I) complexes containing the new bis(1,2,4-triazol-1-yl)acetate ligand.
Marzano C; Pellei M; Colavito D; Alidori S; Lobbia GG; Gandin V; Tisato F; Santini C
J Med Chem; 2006 Dec; 49(25):7317-24. PubMed ID: 17149861
[TBL] [Abstract][Full Text] [Related]
12. DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media.
Novakova O; Chen H; Vrana O; Rodger A; Sadler PJ; Brabec V
Biochemistry; 2003 Oct; 42(39):11544-54. PubMed ID: 14516206
[TBL] [Abstract][Full Text] [Related]
13. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
[TBL] [Abstract][Full Text] [Related]
14. Coordination of 9-ethylguanine to the mixed-ligand compound alpha-[Ru(azpy)(bpy)Cl2] (azpy = 2-phenylazopyridine and bpy = 2,2'-bipyridine). An unprecedented ligand positional shift, correlated to the cytotoxicity of this type of [RuL2Cl2] (with L = azpy or bpy) complex.
Hotze AC; van der Geer EP; Caspers SE; Kooijman H; Spek AL; Haasnoot JG; Reedijk J
Inorg Chem; 2004 Aug; 43(16):4935-43. PubMed ID: 15285670
[TBL] [Abstract][Full Text] [Related]
15. Half-sandwich Ru II[9]aneS3 complexes structurally similar to antitumor-active organometallic piano-stool compounds: preparation, structural characterization and in vitro cytotoxic activity.
Bratsos I; Jedner S; Bergamo A; Sava G; Gianferrara T; Zangrando E; Alessio E
J Inorg Biochem; 2008; 102(5-6):1120-33. PubMed ID: 18279961
[TBL] [Abstract][Full Text] [Related]
16. Chlorido-, aqua-, 9-ethylguanine- and 9-ethyladenine-adducts of cytotoxic ruthenium arene complexes containing O,O-chelating ligands.
Melchart M; Habtemariam A; Parsons S; Sadler PJ
J Inorg Biochem; 2007 Nov; 101(11-12):1903-12. PubMed ID: 17582501
[TBL] [Abstract][Full Text] [Related]
17. Arene control over thiolate to sulfinate oxidation in albumin by organometallic ruthenium anticancer complexes.
Hu W; Luo Q; Ma X; Wu K; Liu J; Chen Y; Xiong S; Wang J; Sadler PJ; Wang F
Chemistry; 2009 Jul; 15(27):6586-94. PubMed ID: 19533706
[TBL] [Abstract][Full Text] [Related]
18. Study of ruthenium(II) complexes with anticancer drugs as ligands. Design of metal-based phototherapeutic agents.
Cini R; Tamasi G; Defazio S; Corsini M; Zanello P; Messori L; Marcon G; Piccioli F; Orioli P
Inorg Chem; 2003 Dec; 42(24):8038-52. PubMed ID: 14632524
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine).
Velders AH; Bergamo A; Alessio E; Zangrando E; Haasnoot JG; Casarsa C; Cocchietto M; Zorzet S; Sava G
J Med Chem; 2004 Feb; 47(5):1110-21. PubMed ID: 14971891
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic activity, X-ray crystal structures and spectroscopic characterization of cobalt(II), copper(II) and zinc(II) coordination compounds with 2-substituted benzimidazoles.
Sánchez-Guadarrama O; López-Sandoval H; Sánchez-Bartéz F; Gracia-Mora I; Höpfl H; Barba-Behrens N
J Inorg Biochem; 2009 Sep; 103(9):1204-13. PubMed ID: 19628280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
